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Abstract The purpose of this brief review is to prepare
readers who may be unfamiliar with Human Immunodefi-
ciency Virus/Acquired Immune Deficiency Syndrome
(HIV/AIDS) and the rapidly accumulating changes in the
epidemic by providing an introduction to HIV disease and its
treatment. The general concepts presented here will facilitate
understanding of the papers in this issue on HIV-associated
neurocognitive disorders (HAND). Toward that end, we
briefly review the biology of HIV and how it causes disease
in its human host, its epidemiology, and how antiretroviral
treatments are targeted to interfere with the molecular biology
thatallows the virus toreproduce.Finally, wedescribewhatis
known about how HIVinjures the nervous system, leading to
HAND, and discuss potential strategies for preventing or





HIV Biology and Pathogenesis
Human immunodeficiency virus type 1 (HIV-1) principally
infects a subgroup of immune cells called activated CD4
+
lymphocytes, and secondarily infects macrophages, also a
cellular component of the immune system. While infected
macrophages are far fewer in number than lymphocytes,
they are believed to be particularly important in the central
nervous system (CNS). Mature viral particles feature a
glycoprotein coat, or envelope, that allows them to identify,
attach to, and enter these specific cell types.
At the earliest stage of its life cycle after infecting CD4
+
lymphocytes and macrophages, HIV directs these host cells
to manufacture a viral enzyme, reverse transcriptase, which
then converts viral RNA into DNA for insertion into the host
cell’s genetic library. HIV has no proofreading enzymes to
correct for RNA to DNA conversion errors, leading to
frequent DNA base substitutions and rapid genetic mutation.
This propensity for copying errors is a major reason that HIV
frequently develops resistance to therapy (see below).
Furthermore, the fact that HIV DNA resides dormant, or
replicatively inactive, in many cells protects it from detection
by the immune system, making eradication of infection
impossible even with the best available therapies.
HIV causes CNS disease in two general ways. Primary
HIV CNS diseases are those for which the virus is both
necessary and sufficient, while secondary CNS diseases
require another, opportunistic pathogen that takes advan-
tage of progressive immune deficiency. Although there is
abundant evidence of primary HIV CNS injury, the virus
does not directly infect neurons, and instead causes
neuronal damage indirectly by infecting macrophages and
other cells in the CNS.
Disease Staging
The clinical course of untreated HIV infection proceeds
through four stages, which may or may not be apparent to
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asymptomatic incubation lasting 2–4 weeks, followed by a
symptomatic acute infection stage lasting 4 weeks on
average (Kahn and Walker 1998). The symptoms of acute
HIV infection are quite similar to those of many other viral
infections, and therefore may pass without detection of
HIV. Next follows a relatively silent period of ongoing viral
replication and immune destruction known as the latency
stage (Gottlieb et al. 2002). Its duration varies significantly,
lasting anywhere from weeks to over a decade. During this
time, patients may feel relatively well, again masking
detection of the virus.
Left untreated, however, HIV almost always causes
progressive immune system destruction, evidenced by
drops in the numbers of CD4
+ and CD8
+ T cells (Laurence
1993). The result is acquired immune deficiency syndrome
(AIDS), which is characterized by susceptibility to various
opportunistic infections. AIDS is diagnosed when the
immune system composition is altered below a threshold
percentage or when T cell quantity is too low. According to
the Centers for Disease Control’s (CDC) 1993 standards, an
HIV-infected individual has AIDS when either (a) their
CD4
+ cells fall to fourteen percent or less of total
lymphocytes, or (b) when the CD4
+ count is less than 200
cells/µL or (c) when at least one of a specific set of
opportunistic infections or neoplasms occurs (Centers for
Disease Control and Prevention 1992). Current HIV
treatment guidelines suggest starting combination antire-
troviral therapy (cART) only in patients with advanced
disease as defined by specific criteria that are revised on an
annual basis (Hammer et al. 2008).
HIV replication is measured by quantifying the viral
load, defined as the number of viral RNA copies per
milliliter of blood plasma. Patients who maintain good
adherence to cART often achieve reduction of the viral load
to undetectable levels, curbing the destruction of CD4
+ T
lymphocytes (Gulick et al. 1997), but not eradicating the
virus which reemerges in nearly all patients when cART is
stopped. As these lymphocytes repopulate their numbers,
the immune system regains strength. Thus cART frequently
results in substantial immune reconstitution in HIV-infected
individuals (Palella et al. 1998).
Antiretroviral Therapy
Since 1996, cART—also known as highly active antire-
troviral therapy, or HAART—has produced dramatic
improvements in health and longevity for HIV-infected
individuals (Palella et al. 1998). cART options usually
consist of three medications representing at least two
different classes of antiretroviral drugs (see below).
Multiple drugs from different classes are required because
new mutations—including those that confer resistance to
single drug or classes—arise at staggering rates. By
inhibiting HIV replication at several stages in the viral life
cycle, cART markedly reduces the likelihood that drug
resistance will develop.
cART regimens typically include two nucleoside (or
nucleotide) analogue reverse transcriptase inhibitors
(NRTIs) and either a protease inhibitor or a non-
nucleoside reverse transcriptase inhibitor (NNRTI). NRTIs
and NNRTIs both interfere with reverse transcriptase
function, preventing new viral particles from being formed.
Nucleoside RTIs differ from their non-nucleoside counter-
parts in how they are designed to interfere with HIV reverse
transcriptase. NRTIs interact with the chemically active
binding site to prevent enzyme activity. However, NNRTIs
bind to an allosteric regulation site, altering the transcrip-
tase enzyme’s shape and function. Protease inhibitors, the
third component to most cART regimens, prevent the
processing of manufactured viral particles through inhibi-
tion of HIV protease. Other classes of antiretroviral drugs
include the integrase enzyme inhibitors, viral entry (fusion)
inhibitors, and HIV maturation inhibitors. A regimen
commonly prescribed to naïve patients is efavirenz (an
NNRTI) plus tenofovir and emtricitabine (NRTIs) coformu-
lated as a single pill given once a day, known as atripla.
Judicious use of antiretroviral therapy, by suppressing
viral replication and partially restoring immune function,
can prevent opportunistic infections and markedly prolong
survival with HIV. As a result, most HIV brain disorders in
the developed world today result not from opportunistic
infections, but from primary HIV disease of the nervous
system (Langford et al. 2003b).
HIV Epidemiology
According to estimates from the 2008 UNAIDS report on
the global AIDS epidemic, there were approximately 33.2
million people living with HIV worldwide at the end of
2007 (Joint United Nations Programme on HIV/AIDS
[UNAIDS] 2008). As prevention and treatment services
have become more accessible, HIV-related deaths have
declined—in 2007 there were 2.1 million HIV-related
deaths worldwide, compared to 3.1 million in 2005
(UNAIDS 2008). These improvements in incidence and
mortality have not been consistent throughout the world,
occurring principally in developed countries. Although the
HIV epidemic has stabilized somewhat since 2000—in that
the annual number of new HIV infections has declined from
approximately 3.0 million in 2001 to 2.7 million in 2007—
the overall number of people living with HIV has steadily
increased because new infections occur each year, and HIV
treatment prolongs survival (UNAIDS 2008).
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Western countries, the virus itself is most prevalent and
least-controlled in resource-limited settings such as sub-
Saharan Africa and South and Southeast Asia (Centers for
Disease Control and Prevention 2008; Sotrel and Dal Canto
2000). Although sub-Saharan Africa accounts for just over
10% of the world’s population, the number of people living
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approximately 22 million, making sub-Saharan Africa
home to 67% of all people living with HIV (UNAIDS
2007). AIDS remains the leading cause of death in this
region, with 76% of all HIV-related deaths in 2007
occurring here (McCutchan 2006). In the same year, it is
estimated that out of the 2.7 million new HIV infections
worldwide, almost two thirds occurred in sub-Saharan
Africa (UNAIDS 2007).
In Asia the number of people living with HIVat the end
of 2007 was around 5.0 million, with the highest and fastest
growing HIV infection levels concentrating in Southeast
Asia (Centers for Disease Control and Prevention 2007).
Epidemics in Indonesia, Pakistan, and Viet Nam are
soaring. In Viet Nam alone, between 2000 and 2005, the
number of people living with HIV more than doubled
(UNAIDS 2007). Although sub-Saharan Africa remains
the most seriously affected region by the AIDS epidemic,
the most concerning increases in the incidence of new
HIV infections are occurring in Eastern Europe and
Central Asia. In this region, an estimated 1.6 million
people were living with HIV at the end of 2007, an
increase in prevalence of 150% since 2002 (UNAIDS
2007) .W o r s ta f f e c t e da r eR u s s i aa n dU k r a i n e ,w i t h6 2 %
of infections attributable to intravenous drug use
(UNAIDS 2008).
In North America and Western and Central Europe there
were approximately 2.0 million people living with HIV at
the end of 2007—the United States accounting for an
estimated 1.2 million of these (UNAIDS 2008).
Women account for half of all people living with HIV
worldwide—at the end of 2007 an estimated 15.4 million
women were infected with HIV (UNAIDS 2008). The
proportion of women living with HIV varies significantly
between different regions of the world, with a higher
burden in sub-Saharan Africa and the Caribbean. For
example, in sub-Saharan Africa women comprise nearly
61% of all adults living with HIV, while in the United
States only 25% of people living with HIV are women
(Centers for Disease Control and Prevention 2007;
UNAIDS 2007). Over the last 10 years, the number of
women living with HIV globally has remained stable, but in
Latin America, Asia, and Eastern Europe this number is
slowly increasing as they are infected by their male partners
who are likely to have been infected through injecting drug
use, or unprotected sex (UNAIDS 2007). In addition to the
direct impact that HIV has on these women, there is also a
known risk of mother-to-child transmission.
HIV Subtypes
HIV infections worldwide are characterized according to
subtypes (clades), reflecting variants that are genetically
more related to one another and often cluster in
geographic regions because of founder effects. The high
overall genetic diversity that characterizes HIV has been
a key factor in its worldwide spread, and poses concerns
for disease progression, as well as diagnosis, treatment
and prevention efforts (Hemelaar et al. 2006). Findings
from studies conducted in Western countries derive mainly
from work on HIV-1 clade B infection in Caucasian
populations, and therefore may not be generalizable to
HIV clades and human populations globally. HIV-1 clade
B is responsible for only 10% of infections worldwide and
predominates in Western Europe, Australia, and the
Americas (McCutchan 2006). In the United States, HIV-
1 clade B represents the vast majority of infections (98%)
with only minor contributions by other clades (Hemelaar
et al.). However, in sub-Saharan Africa—the region most
affected by the HIV epidemic—HIV-1 clade C is most
common, accounting for about 50% of infections world-
wide. In other areas heavily affected by the HIVepidemic,
such as South and Southeast Asia, the predominant
subtype is HIV-1 Clade AE. Finally, in Eastern Europe,
Russia, and populous areas of Asia where the epidemic is
rapidly expanding, 79% of infections are caused by HIV-1
clade A (Hemelaar et al.).
The effects of HIV subtypes, or clades, on disease
progression and treatment remain unclear (Liner et al.
2007). While numerous studies indicate that reverse
transcriptase inhibitors and protease inhibitors are equally
effective treating all HIV subtypes (Alexander et al. 2002;
Bocket et al. 2005; Pillay et al. 2002), other studies claim
that different HIV subtypes are more efficient in developing
antiretroviral resistance, and present diminished drug
sensitivity and HIV pathogenicity (Eshleman et al. 2001;
Kantor et al. 2005; Spira et al. 2003).
Mechanisms of HIV-Associated Injury
HIV infection results in disruption of neuronal function
by a variety of mechanisms that can be grouped into
three general categories: viral factors, host factors and
co-factors. Viral factors derive from the virus itself, and
include several proteins encoded by the viral genome.
Host factors, on the other hand, evolve indirectly or
secondarily from infection, but may damage even
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behavioral characteristics or co-morbid conditions that
may contribute to or amplify the pathogenicity of HIV.
In the nervous system, these factors converge in
producing damage to the elaborate network of connec-
tions between neurons that take place at dendrites and
synapses. This synaptodendritic injury, described in
detail below, disrupts the highly integrated functioning
of neural systems that is required to process information,
leading to HIV-associated neurocognitive disorders
(HAND). As discussed in more detail in other manu-
scripts in this series, HIV associated dementia (HAD) is
the most severe form of HAND. The brain, however,
does not respond passively to synaptodendritic injury,
but instead actively upregulates pathways promoting
repair and regeneration. These pathways have become
particularly important today, as survival has been
prolonged by cART. Because both viral and host factors
play a role in HAND, effective treatment might require
both cART and so-called “adjunctive” therapies that
include neuroprotective and neuroregenerative agents.
Neurotoxic Viral Factors The HIV genome codes for a
variety of proteins that can damage neuronal cells and
interfere with CNS function. Two of the more important
viral proteins shown to be neurotoxic are gp120, the virus’s
envelope protein, and transactivator of transcription (Tat).
gp120 is necessary for infectivity, but also interacts with
host cellular receptors to alter glutamate pathway signaling
and induce cytokine production that can injure neurons and
affect the activation state of microglia and astrocytes.
Patterns of neuronal injury seen in the brains of cognitively
impaired HIV-infected individuals that come to autopsy can
be replicated in cultures of human nervous tissue exposed
to gp120 (Iskander et al. 2004) and in transgenic mice that
express HIV-1 gp120 in the brain (Toggas et al. 1994).
These changes include synaptodendritic injury, reactive
astrocytosis, and microgliosis, and loss of large pyramidal
neurons (Kaul and Lipton 2005). One molecular mechanism
by which gp120 might induce these changes is through
glutamate-mediated excitotoxicity, which can initiate cas-
pase cascades (Tenneti and Lipton 2000).
Another viral protein reported to cause neuronal injury is
Tat, which is produced by infected astrocytes (Nath 2002). In
experiments in which Tat-expressing astrocytes were injected
into the rat dentate gyrus, Tat was taken up by granule cells
and transported along neuronal pathways to the CA3 region
of the hippocampus, where it caused glial cell activation and
neurotoxicity (Bruce-Keller et al. 2003). HIV Tat can cause
mitochondrial dysfunction, dendritic loss, and cell death in
neurons at concentrations lower than those needed to support
viral replication (Chauhan et al. 2003).
Neurotoxic Host Factors Secondary effects of HIV infec-
tion on the immune system can amplify nervous system
damage. Many of the host factors relevant to HIV CNS
injury are chemical mediators of inflammation and immu-
nity—cytokines and chemokines. Cytokines are produced
by immune cells including macrophages that traffic into the
CNS from the peripheral circulation, as well as by brain
astrocytes and microglia activated or infected by HIV.
Chemokines represent a subset of cytokines with chemo-
attractant properties, and are particularly important in HIV-
related pathology. Chemokine receptors are distributed
throughout the brain on microglia, astrocytes, oligodendro-
cytes and neurons.
Abnormal activation of cytokine and chemokine recep-
tors results in ultrastructural and functional neuronal
alterations that are at least partially reversible. This suggests
that appropriate treatments might enhance neuronal repair
and ameliorate the damage arising from abnormal activa-
tion of cytokine or chemokine receptors. Importantly, host
factors can differ between individuals. For example,
increased susceptibility to neurodegeneration in HIV is
associated with host genetic variations that might account
for differential susceptibility to HAND between different
individuals infected with the same viral strain (Gonzalez et
al. 2002; Quasney et al. 2001).
Cofactors in CNS Injury HIV-infected individuals frequent-
ly have co-morbidities such as abuse of drugs and alcohol
or infection with viral co-pathogens such as hepatitis C
virus (HCV). These cofactors may contribute to CNS
injury. For example, in neuropathological studies, HIV-
infected individuals dying with histories of injection drug
use show more activated microglia and diffuse astrogliosis
in the white matter of the brain than their HIV-infected non-
addicted counterparts (Cook et al. 2005; Persidsky et al.
1996; Langford et al. 2003b) found that those dying with
HIV and a history of methamphetamine addiction had
greater loss of calbindin-immunostaining interneurons than in
those with either condition alone. In vitro studies (Bagasra et
al. 1993) as well as studies with rhesus monkeys (Tyor and
Middaugh 1999) and mice (Winsauer et al. 2002)s u g g e s t
that alcohol may exacerbate the immunological abnormali-
ties associated with HIV infection, specifically the peripheral
immune system. In addition, several studies have demon-
strated that HCV co-infection was associated with a greater
risk of neurocognitive disorders among those with HIV, with
or without drug use (Cherner et al. 2004; Morgello et al.
2005). Because HCV is also associated with systemic and
possibly CNS immune activation, it is possible that there
may be some common immuno-neuropathogenic mecha-
nisms leading to a heightened likelihood of CNS disease in
co-infected individuals.
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Synaptodendritic injury is a general term encompassing a
variety of structural and chemical changes that ultimately
can impair the normal functioning of neuronal networks.
Normal synaptodendritic networks are complex and highly
branching, whereas injured networks are simplified. Fea-
tures of syndaptodendritic injury include dendritic spine
retraction, beading and aberrant sprouting. Higher cognitive
functions depend on the integrity of complex synaptoden-
dritic networks, therefore damage results in deficient
cognitive skills and behavior.
Synaptodendritic injury is demonstrated by immunos-
taining with antibodies to presynaptic synaptophysin
(SYN) and postsynaptic microtubule associated protein-
2 (MAP2) (Orenstein et al. 1988). MAP2 is expressed on
neuronal cell bodies and dendrites. In HIV-infected
individuals, the degree of neurocognitive impairment is
strongly related to loss of immunostaining for SYN and
MAP2 (Moore et al. 2006). This technique has provided
evidence that the striatum and the hippocampus are
particularly affected (Bruce-Keller et al. 2003;M o o r ee t
al. 2006). This regional vulnerability parallels the higher
burden of HIV proteins and viral RNA in the striatum and
white matter connecting the striatum to the prefrontal
cortex (Masliah et al. 1997).
Techniques for measuring synaptodendritic injury in
living humans are indirect and imprecise. Proteins released
from damaged neurons into the extracellular space can be
detected in the cerebrospinal fluid (CSF) or blood. Elevated
CSF neurofilament protein (NFL) concentrations, for
example, are thought to reflect injury to myelinated axons.
CSF NFL levels are increased both in the context of HIV
dementia (Arnold 2001; Law et al. 2004) and after the
interruption of cART, which results in a significant rebound
of HIV replication. However, it is not known whether
increased NFL can result from neuronal injury alone or
requires cell death, and there are no data on the dynamic
relationship between changes in neurological status in HIV
patients and changes in NFL levels.
It is reasonable to propose that synaptodendritic loss
will reduce the overall volume of brain gray and white
matter. Gross structural atrophy can be visualized by
brain computed tomography (CT) and magnetic reso-
nance imaging (MRI), and careful radiological-
neuropathological correlation studies have shown that
white matter loss and abnormal white matter signal are
closely correlated with the loss of MAP-2 immunostain-
ing, particularly in the presence of HIV encephalitis
(Archibald et al. 2004). Worsening white matter abnor-
malities correlate with worsening cognitive impairment
(Everall et al. 1999).
Nervous System Repair
Synaptic dendritic networks in the healthy brain undergo
continuous remodeling, reflecting plasticity, which can
include increased dendritic branching, augmentation of
axonal collaterals, generation of new synaptic connections
and activity-dependent modification of existing synapses
(Makrigeorgi-Butera et al. 1996). Various mediators of
CNS plasticity may include brain derived neurotrophic
factor (BDNF), insulin-like growth factor 1 (IGF-1), acidic
fibroblast growth factor (aFGF, FGF1), macrophage in-
flammatory protein-2 (MIP2), stromal-derived factor-
1alpha (SDF-1α) and leptin (Isackson 1995; Pezet and
Malcangio 2004; Shanley et al. 2001). Neurogenesis may
also participate in restoration of function after brain injury
(Langford et al. 2003a; Tomlinson et al. 1999).
HIV-Associated Neurocognitive Disorders
NeurodegenerationandsynaptodendriticinjuryinHIV-infected
individuals result in the clinical syndromes of HAND. Neuro-
cognitive disorders can range in severity from slight deficits to
debilitating dementia. In 2007 the National Institute of Mental
Health (NIMH) and the National Institute of Neurological
Diseases and Stroke (NINDS), commissioned the development
of updated, working research criteria for HAND, based on
criteria proposed by the San Diego HIV Neurobehavioral
Research Center (HNRC). The resulting criteria defined three
conditions: asymptomatic neurocognitive impairment (ANI),
HIV-associated mild neurocognitive disorder (MND), and
HIV-associated dementia (HAD) (Antinori et al. 2007). ANI
describes individuals with usually mild impairment in two or
more cognitive areas, demonstrated by neuropsychological
testing, without a clear effect on everyday functioning. MND
refers to the presence of mild to moderate deficits in two or
more cognitive areas which create at least mild interference in
everyday functioning. Finally, HAD describes individuals
with documented moderate to severe deficits in two or more
cognitive areas, with substantial impairment in every day
functioning making the person incapable of employment and
often unable to live independently.
Since the introduction of cART in 1996, the incidence of
HAD, the more severe form of HAND, has decreased
(McArthur 2004; McArthur et al. 1999). Despite this, the
overall prevalence of HAND has not declined, possibly
because HIV infected individuals with milder neurocognitive
disorders are living longer, or because cART is not as
effective in the brain as in the periphery. Thus milder
impairments persist in many patients, with prevalence ranging
between 30% and 50% depending in part upon disease stage,
as documented in several reports in this volume.
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The notion that cART might not be as effective in the brain
as it is systemically derives from the observation that the
blood brain barrier (BBB) frequently limits the movement
of antiretrovirals from the circulation into the CNS. Several
factors affect the CNS penetration of antiretroviral medi-
cations. Tight junctions between brain endothelial cells
prevent the diffusion of polar molecules, making non-
polarity (lipophilicity) an important determinant of CNS
penetration (Strazielle and Ghersi-Egea 2005). Highly
protein-bound drugs have lower unbound concentrations,
so fewer drug molecules are available to cross the BBB
(Langford et al. 2006; Wynn et al. 2002). Once a drug does
cross the BBB, efflux transporters—cellular proteins that
pump various molecular substrates—may then promptly
push it back into the circulation. As a result, HIV
replication may persist in the CNS, despite adequate
peripheral suppression (Blankson et al. 2002; De Luca et
al. 2002; Wong et al. 1997).
The degree of penetration of antiretroviral therapy into
the CNS seems to influence the extent of neurocognitive
improvement, with individuals on regimens containing
more CNS-penetrating drugs presenting better CSF viral
load suppression (Letendre et al. 2004). Also, optimal
antiretroviral concentrations in the CNS may be necessary
to limit local HIV replication and prevent the development
of drug-resistant viral strains in the CSF, which have the
potential to re-infect the periphery (Reddy et al. 2003).
Studies are ongoing to address the question of whether
choosing antiretrovirals with greater CNS penetration will
improve neurocognitive outcomes in HAND.
Beyond antiretroviral therapy, there is considerable
interest in treating HAND with agents that promote
neuronal repair or prevent further injury, so-called neuro-
protective or regenerative therapies. For example, lithium,
which is used to treat bipolar disorder, also modulates the
expression of the pro-apoptotic glycogen synthase kinase
3β (GSK3β). In vitro, lithium prevents the induction of
dendritic spine loss and simplification by HIV gp120
(Everall et al. 2002), indicating that it might be useful in
HIV. In humans with HAND, lithium administration was
associated with improved neurocognitive performance in a
single-arm, 12-week study (Letendre et al. 2006). Minocy-
cline is an antibiotic that has anti-inflammatory and neuro-
protective effects that are currently being studied in humans.
Memantine, a non-competitive antagonist of the NMDA
receptor, prevents Tat and gp120-induced intracellular
calcium increases and glutamate toxicity (Chen et al. 1998;
Lipton and Chen 2004;N a t he ta l .2000; Toggas et al. 1996).
Early clinical trials suggest that some of these agents may
have benefits, but none has been subjected to rigorous
scientific evaluation in large, phase III licensing studies.
Summary and Conclusions
Understanding central nervous system injury in HIV
infection requires an appreciation of some of the complex-
ities of disease progression and its treatment. The outlook
for patients with HIV has improved dramatically as
increasingly effective antiretroviral therapies have become
available. Nevertheless, neurocognitive impairment remains
quite prevalent and is associated with reduced quality of life
and social and occupational disabilities. Since HIV, with
treatment, has become a chronic, manageable disease, the
neurocognitive aspects of this condition should become an
important focus for future research on pathogenesis and
treatment.
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